Is Semaglutide Available for Weight Loss? Exploring the Facts and Options

Last reviewed: June 11, 2026

Last updated: June 11, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Yes — semaglutide is available for weight loss in the United States, but only under one brand name. According to the Wegovy prescribing information, Wegovy is the semaglutide product indicated to reduce excess body weight and maintain weight reduction long term in adults with obesity, in adults with overweight plus at least one weight-related comorbid condition, and in pediatric patients aged 12 years and older with obesity. The other semaglutide products on the U.S. market — Ozempic injection, and the Rybelsus and Ozempic tablets — are approved for type 2 diabetes, not for weight management. Same molecule, different applications, different labels, and the distinction determines what a pharmacy can dispense and what a plan will pay for.

Wegovy Is the Semaglutide Product Approved for Weight Loss

Wegovy's labeled indications go well beyond a single line about weight. The prescribing information lists weight reduction and long-term maintenance in the populations above, reduction of major adverse cardiovascular event risk in adults with established cardiovascular disease and either obesity or overweight, and treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis. All of the weight-related uses are described in combination with a reduced-calorie diet and increased physical activity — the label frames the medication as an adjunct, not a replacement.

The label also carries an explicit limitation of use: concomitant use of Wegovy with other semaglutide-containing products, or with any other GLP-1 receptor agonist, is not recommended. That single sentence rules out a surprising number of the stacking ideas that circulate online.

It is worth reading the indication statement closely rather than the headline. "Reduce excess body weight and maintain weight reduction long term" is a maintenance claim as much as a loss claim, and the trials behind it ran 64 to 72 weeks. This is labeled as chronic therapy for a chronic condition, which is a different proposition from a short course.

Ozempic and the Diabetes Tablets Are Not Weight-Loss Approvals

The Ozempic prescribing information lists three indications, all in adults with type 2 diabetes: improving glycemic control as an adjunct to diet and exercise, reducing the risk of major adverse cardiovascular events in those with established cardiovascular disease, and reducing the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in those with chronic kidney disease. Weight management appears nowhere in that list, and there is no body mass index threshold anywhere in the label.

The same is true on the oral side. The current label covering Rybelsus and Ozempic tablets describes Rybelsus at 3, 7 and 14 mg and Ozempic tablets at 1.5, 4 and 9 mg, both for type 2 diabetes and cardiovascular risk reduction. People often assume any semaglutide product is interchangeable for weight loss. The regulatory record says otherwise.

The consequence is administrative as much as clinical. Pharmacy benefit design, prior authorization criteria and diagnosis coding all key off the approved indication, so a prescription for the wrong brand can be denied for reasons that have nothing to do with whether the molecule would work for you.

Semaglutide for Weight Loss Now Comes as a Tablet

The Wegovy label covers two dosage forms. Alongside the injection, it now includes Wegovy tablets at 1.5, 4, 9 and 25 mg, with 25 mg once daily described as the maintenance dosage for cardiovascular risk reduction and weight reduction in adults. That matters for anyone who has ruled out treatment because of needles.

The tablets are not simply an oral copy of the injection. They carry a narrower set of indications than the injection does — the pediatric and liver-disease uses sit with the injection only — and they have their own administration requirements built into the label. Which form is appropriate is a prescriber conversation, informed by what each label supports.

What the Weight-Loss Trials Actually Showed

The pivotal evidence is in the label and in the peer-reviewed literature. In the 68-week trial reported in the Wegovy label as Study 2 — published as STEP 1 in the New England Journal of Medicine, enrolling 1,961 adults without diabetes — mean body weight change was −14.9% with semaglutide 2.4 mg versus −2.4% with placebo. In the published analysis, 86.4% of the semaglutide group achieved at least 5% weight reduction versus 31.5% on placebo, and 50.5% achieved at least 15% versus 4.9%.

Two companion trials in the label tell a more textured story. In adults with type 2 diabetes and obesity or overweight, the mean change was −9.6% versus −3.4% with placebo — a real effect, but a smaller one. Averages are not predictions, and the spread around them is wide.

Long-term data exist as well. In the cardiovascular outcomes trial reported in the Wegovy label as Study 1, mean body weight change at week 104 was −9.4% with semaglutide injection versus −0.93% with placebo in a population enrolled for cardiovascular risk rather than for weight loss, with a median follow-up of 41.8 months.

The Higher-Dose Option in the Current Label

The Wegovy label now includes a 7.2 mg once-weekly presentation, marketed as Wegovy HD. In the 72-week trial the label calls Study 8, mean percent change in body weight was −18.8% at 7.2 mg, −15.5% at 2.4 mg, and −3.9% with placebo. Discontinuation from adverse reactions was 5.4% at 7.2 mg versus 1% on placebo.

More dose produced more weight change and more discontinuation, which is the trade-off that runs through this entire drug class. Whether a higher maintenance dose is appropriate for a given person is a clinical judgment, not a preference to be selected from a menu.

Compounded Semaglutide Is a Separate Category

Compounded semaglutide is not an FDA-approved finished product. The FDA does not review compounded preparations for safety, effectiveness or quality before they are marketed, and a compounded preparation is not a generic version of Wegovy or Ozempic — neither brand has an approved generic. It is prepared by a licensed pharmacy pursuant to a prescription for an individual patient.

The FDA has been direct about the risks it has seen. Its safety communication on unapproved GLP-1 drugs describes adverse event reports involving dosing and measurement errors, some requiring hospitalization, and separately flags products sold under "research purposes only" labeling. Sourcing matters, and so does whether an actual prescriber is involved.

What Determines Whether You Can Actually Get It

Availability is a chain, not a single yes or no. A prescriber has to determine that treatment is clinically appropriate for you. A pharmacy has to be able to fill it. And a plan, if you are using one, has to agree to pay — which for weight management is often the hardest link.

Each of those three can fail independently. Understanding which one is blocking you is the fastest route to solving it, and it is a very different conversation depending on whether the obstacle is clinical, logistical or financial.

The most common mistake is treating a coverage denial as a clinical verdict. A denial usually means the documentation did not match the plan's prior authorization criteria, not that treatment is inappropriate. Asking the plan for the specific criteria it applied turns a dead end into a checklist.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Is semaglutide approved by the FDA for weight loss?

Yes, under the brand name Wegovy. The Wegovy prescribing information indicates it to reduce excess body weight and maintain weight reduction long term in adults with obesity, in adults with overweight plus at least one weight-related comorbid condition, and in pediatric patients aged 12 years and older with obesity, all in combination with a reduced-calorie diet and increased physical activity. Ozempic, Rybelsus and Ozempic tablets are approved for type 2 diabetes instead.

Can I use Ozempic instead of Wegovy for weight loss?

The Ozempic label does not include a weight-management indication. Its three indications all concern adults with type 2 diabetes: glycemic control, cardiovascular risk reduction in established cardiovascular disease, and kidney and cardiovascular outcomes in chronic kidney disease. A licensed clinician may prescribe an approved drug outside its labeled indication when they judge it appropriate, but that is a prescriber decision and it does not change the approval status or obligate any insurer to cover it.

Is there a semaglutide pill for weight loss?

Yes. The Wegovy label now covers Wegovy tablets at 1.5, 4, 9 and 25 mg, with 25 mg once daily described as the maintenance dosage for cardiovascular risk reduction and weight reduction in adults. The tablets carry a narrower set of indications than the Wegovy injection does. Separately, Rybelsus and Ozempic tablets are oral semaglutide products approved for type 2 diabetes rather than for weight management.

How much weight did people lose in the semaglutide trials?

In the 68-week STEP 1 trial of 1,961 adults without diabetes, mean body weight change was minus 14.9% with semaglutide 2.4 mg versus minus 2.4% with placebo, and 50.5% of the semaglutide group lost at least 15% of body weight. In the 72-week trial the Wegovy label calls Study 8, mean change was minus 18.8% at 7.2 mg, minus 15.5% at 2.4 mg and minus 3.9% with placebo. Individual results vary widely.

Is compounded semaglutide the same as Wegovy?

No. Compounded semaglutide is not an FDA-approved finished product, and the FDA does not review compounded preparations for safety, effectiveness or quality before marketing. It is prepared by a licensed pharmacy pursuant to a prescription for an individual patient. It is not a generic version of Wegovy or Ozempic, because neither brand has an approved generic equivalent. The FDA has published safety concerns about unapproved and improperly sourced GLP-1 products.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.